[ad_1] Posted Monday November 23, 2020 BrainEver, a biotech company dedicated to the research and development of innovative therapies for the treatment of neurodegenerative diseases, today announces that the FDA (Food and Drug Administration) in the United States has granted orphan drug designation to its BREN-02 product, homeoprotein recombinant human …
Read More »BrainEver: FDA orphan drug designation for BREN-02 for the treatment of ALS MyPharma editions
